Can mesenchymal stem cell therapy be the interim management of COVID-19?

Bamba, Chitra; Singh, Surinder P.; Choudhury, Sangeeta

doi:10.5582/ddt.2020.03032

Cited by 19 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the promising immune-modulators is the MSCs administered as add-on therapy can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients [163].…”

Section: Msc Clinical Studiesmentioning

confidence: 99%

Cellular Therapy as Promising Choice of Treatment for COVID-19

Irmak¹,

Karaöz²

2022

Biotechnology to Combat COVID-19

View full text Add to dashboard Cite

In the pandemic of COVID-19, while living normals have been changing, there have been a huge effort globally to find out effective and safe treatment agents and vaccines. As of now, the advances show the progress in vaccine development, however the treatment of the COVID-19 is yet not fully specified. The drugs, i.e. antibiotics, antivirals, antimalarians, even anti-HIV agents which have been known already were taken out of the shelves and brought into use in different combinations. On the other hand, the cellular treatment, more specifically the mesenchymal stem cell therapy has been encouraged, resulting in various evidence published all over the world. This chapter aims to compile the published information, in means of methods, disease manifestations, results and limitations, about the stem cell treatment of the COVID-19 and to provide a source of harmonized reference for scientific society.

show abstract

Section: Msc Clinical Studiesmentioning

confidence: 99%

Cellular Therapy as Promising Choice of Treatment for COVID-19

Irmak¹,

Karaöz²

2022

Biotechnology to Combat COVID-19

View full text Add to dashboard Cite

show abstract

“…These findings are in line with the previous reports. [18][19][20] However, the role of the inflammatory response in liver damage of COVID-19 infected patients demands further investigation. Mitigation of the cytokine storms through clinical treatment remains crucial in the prognosis of patients with severe COVID-19 infection.…”

Section: A H E a D O F P R I N Tmentioning

confidence: 99%

The clinical characteristics and underlying causes of liver damage in patients with COVID-19 infection: Retrospective analysis

Zuo¹,

Liu

2021

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: 2019-nCoV has become a global threat to human health. The primary objective of this study was to examine the hepatic damage in 2019-nCoV infected patients and the associated underlying causes. Methods: In this retrospective study, a total of 68 laboratory-confirmed and 20 suspected COVID-19 cases from 23rd January 2020 to 15th February 2020 were included. The study was conducted in The First People’s Hospital of Jingzhou, Hubei. SPSS version 23.0. was used for Statistical analysis using the Student’s t-test or Chi-square test. Data was analyzed for the clinical characteristics and underlying causes of liver damage. The outcomes were followed up until March 29, 2020. Results: Out of the 68 COVID-19 confirmed cases, 51 had an abnormal liver function, of which 15 had an abnormal liver function at the time of hospital admission. The relationship between the liver function and clinical prognosis of patients showed that the abnormal liver function was positively correlated with the severity of the infection (100% vs.70.2%, p=0.036). The proportion of patients with an elevated level of ALT and a depleted level of Albumin (ALB) were significantly lower in the COVID-19 suspected group than the confirmed group (5% vs. 50.9%, p=0.000; 10% vs. 35.8%, p=0.030, respectively). Besides, the utilization rate of lopinavir/ritonavir, azithromycin, and methylprednisolone in COVID-19 suspected patients were significantly lower than the confirmed patients (25% vs. 62.3%, p=0.004; 35% vs. 62.3%, p=0.037; 25% vs. 64.2%, p=0.003, respectively). Conclusions: Liver function anomalies are one of the common symptoms associated with the COVID-19 infection, where virus-replication in the liver cells, virus-induced inflammatory response, and administration of clinical medication could be the plausible reason. doi: https://doi.org/10.12669/pjms.37.5.4161 How to cite this:Zuo G, Liu W. The clinical characteristics and underlying causes of liver damage in patients with COVID-19 infection: Retrospective analysis. Pak J Med Sci. 2021;37(5):---------. doi: https://doi.org/10.12669/pjms.37.5.4161 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Currently, stem cell therapy has become a promising therapeutic field, which is showing various opportunities to cure incurable diseases 43 . MSCs has called for attention due to source potential, a high proliferation rate, the need of a less invasive procedure, and free of ethical issues.…”

Section: Mesenchymal Stem Cell Therapymentioning

confidence: 99%

Therapeutic Modalities in the management of COVID-19: A worldwide landscape

Uttamani

Fernandes

Pandey³

et al. 2020

Preprint

View full text Add to dashboard Cite

Several strains of the novel Coronavirus have been identified and countries around the world are conducting research to identify, map and compare each type. Its infection can manifest with symptoms ranging from uncomplicated non-specific illness to a more damaging syndrome that include mild to moderate pneumonia (Co-vid 19 pneumonia broadly categorised into the phenotypes: L-type and H-type); Acute Respiratory Distress Syndrome; Sepsis and Septic shock. Although, this virus has a low mortality rate, the danger lies in its virulence and transmission dynamics. With more and more cases being reported, researchers and clinicians are promptly identifying and triaging the cases for treatment. Till date, there has been no drug identified to be efficacious cure for this infection. Using the WHO guidelines as a base, various medical institutions are continuously updating their guidelines for the identification and therapeutic management of persons infected with Co-vid 19, with a strong emphasis on IPC measures. The guidelines also highlight detailed supportive treatment including supplemental oxygen therapy, ventilation, intubation and management of specific complications. The current treatment is tailored to patient centred management for the existing co-morbidities and appreciate a progress in the prognosis. What is needed at this hour however, is a definitive drug therapy or vaccine. Different countries are rushing to find this and various trials are already underway. The aim of this article is thus to review salient features of specific therapies being used now and summarise the different clinical trials being conducted so as to stay abreast of the possible treatment modalities.

show abstract

Can mesenchymal stem cell therapy be the interim management of COVID-19?

Cited by 19 publications

References 18 publications

Cellular Therapy as Promising Choice of Treatment for COVID-19

Cellular Therapy as Promising Choice of Treatment for COVID-19

The clinical characteristics and underlying causes of liver damage in patients with COVID-19 infection: Retrospective analysis

Therapeutic Modalities in the management of COVID-19: A worldwide landscape

Contact Info

Product

Resources

About